Lab Institute 2014 is pleased to welcome these distinguished speakers. These individuals have demonstrated excellence in the industry and we thank them for sharing their knowledge with the Lab Institute community.
A. Neil Crowson, M.D., FCAP, FRCPC
Chief of Staff, St. Johns Health System; President, Pathology Laboratory Associates and Vice President, Regional Medical Laboratory
Dr. Crowson is currently President of Pathology Laboratory Associates, Vice President of Regional Medical Laboratory and Chief of Medical Staff at St. John Medical Center in Tulsa, OK.
Dr. Crowson joined Pathology Laboratory Associates and Regional Medical Laboratory at St. John Medical Center in April of 1999, coming from Winnipeg, Canada. He did his premed at Queens University in Kingston, Ontario and attended medical school at the University of Manitoba, graduating in 1980. He did his postgraduate training at the University of Toronto in Anatomic Pathology and Hematopathology. He spent fourteen years in Winnipeg doing combined AP and CP and directing the laboratory department at the Misericordia General Hospital and Central Medical Laboratories. Dr. Crowson is a Clinical Professor of Dermatology, Pathology and Surgery at the University of Oklahoma Medical School, where he is Director of Dermatopathology. He has over 320 publications including an award-winning book on melanoma, now in press as a second edition, Textbook of Dermatopathology (McGraw Hill, 2010) which he co-edits with Raymond Barnhill, Cynthia Magro and Michael Piepkorn, Biopsy Interpretation of the Skin (Lippincott, 2010) and The Cutaneous Lymphoid Proliferations (Wiley, 2007). He maintains active research interests in the molecular biology of skin cancer and the inflammatory dermatoses, and directs the 5-day ASCP education course entitled Dermatopathology : Contemporary Diagnostic Criteria and Strategies, on an annual basis.
Ben Davis, M.D.
Chairman & CEO, PathGroup
Ben Davis, M.D. Chairman, President, and Chief Executive Officer of PathGroup, Inc. in Nashville, Tennessee, since its founding in 1996. Dr. Davis has also served as President and Chief Executive Officer of Associated Pathologists during this period. Prior to joining Associated Pathologists in 1986, he was an Assistant Professor in the Department of Pathology, Vanderbilt University Medical Center and School of Medicine after completing a Residency in Anatomic and Clinical Pathology at Vanderbilt in 1981. Dr. Davis received his Undergraduate Degree with a B.A. in Molecular Biology at Vanderbilt University in 1973 and his M.D. at the University of Arkansas School of Medicine in 1977. Other notable experiences include serving as Chairman of the HCA Healthcare Network Institutional Review Board (1989-2008) and as Group Leader of the Experimental Pathology Unit, Ludwig Institute for Cancer Research, Molecular Biology Branch, Bern Switzerland (1981-1983).
Keith Fontenot, MA
Managing Director of Government Relations and Public Policy, Hooper, Lundy & Bookman, PC
Mr. Fontenot is the Managing Director of the Government Relations & Public Policy department of Hooper, Lundy & Bookman, PC. Mr. Fontenot brings to the firm a wealth of experience in health policy at the highest levels of government, in both the Executive and Legislative branches. Most recently, as the top health care budget official at OMB he was heavily involved in the development and implementation of the Affordable Care Act. In his four years in that role, he advised the most senior levels of the White House, the top leadership of key federal health agencies, and members of Congress, on budget, legislative, and regulatory issues in major health programs.
In addition to his four plus years as Associate Director for Health at OMB, Mr. Fontenot served as Deputy Assistant Director for Health and Human Resources at the Congressional Budget Office (CBO), and as Chief of the Health Financing Branch at OMB. In these positions Mr. Fontenot was closely involved in virtually every aspect of health policy, including: the creation of new payment systems in post acute care, major reforms to other payment systems in Medicare, negotiation of Medicaid waivers, and development and implementation of the Medicare prescription drug program. He oversaw cost estimates and related analysis for health, education and income security programs at CBO, and was deeply involved in helping the agency prepare for health reform legislation, including CBO’s development of options such as Accountable Care Organizations.
Mr. Fontenot is also a Visiting Scholar at the Brookings Institution, where he works with former CMS Administrator Mark McClellan on Brookings’ ongoing efforts in health reform. Mr. Fontenot began his federal career as a budget examiner at OMB for Social Security and other retirement programs in 1982. He holds a M.A. in public policy from Duke University, and a B.A. from the Old Dominion University.
Senior Healthcare Analyst, Bloomberg Government
Peter Gosselin is a Senior Healthcare Analyst with Bloomberg Government. He was a special economic adviser for health reform at the Department of Health and Human Services and chief speechwriter to Treasury Secretary Timothy Geithner. Gosselin spent 35 years at newspapers, most recently as chief economics correspondent for the Los Angeles Times. He has a bachelor’s degree from Brown University and an MBA in economics from Columbia Business School
Marc D. Grodman, M.D.
Chairman, Chief Executive Officer and President of Bio-Reference Laboratories Inc.
Dr. Marc D. Grodman, M.D. has been the Chairman, Chief Executive Officer and President of Bio-Reference Laboratories Inc. since December 1981 and serves its Managing Director. Dr. Grodman founded Bio-Reference Laboratories in December 1981. He serves as Secretary of The Actors Fund. He is an Assistant Professor of Clinical Medicine at Columbia University College of Physicians and Surgeons and Assistant Attending Physician at Presbyterian Hospital, New York City. From 1982 to 1984, he served as Medical Consultant to the Metal Trades Department of the AFL-CIO. He serves as the Chairman of CareEvolve.com, Inc. He has been a Director of BioReference Laboratories Inc. since December 1981. He serves as a Trustee of The Actors Fund. Since January 2005, he has been a member of the Board of Directors of the American Clinical Laboratory Association. From 1980 to 1983, he attended the Kennedy School of Government at Harvard University and was a Primary Care Clinical Fellow at Massachusetts General Hospital. Dr. Grodman received a B.A. degree from the University of Pennsylvania in 1973 and an M.D. degree from Columbia University College of Physicians and Surgeons in 1977.
Eleanor Herriman, M.D., M.B.A.
Managing Director, Advisory Services, G2 Intelligence
L. Eleanor J. Herriman, M.D., M.B.A. is a pathologist executive with 15+ years experience in the medical technology industry. She has worked across sectors with both small ventures and corporations. Her market experience spans the clinical laboratory, in vitro diagnostics, e-health, biotech, and strategy consulting for Bain & Company. Other key accomplishments include growing a venture with a CLIA lab and FDA PMA approved computer-assisted cytology instrument from start-up to publicly traded company (IPO raised $100 million).
She is the leader of G2 Intelligence’s advisory services, which provides strategic consulting and custom market research and assessments for a range of clients, including pathology groups, clinical labs, health systems, hospitals, medical centers, diagnostic technology companies, and investors.
She is the author of three G2 reports: Health Care Market Reforms: Implications and Prescriptions for Laboratories; How to Build a Molecular Testing Laboratory: Key Strategic & Operational Considerations; and Creating a Value-Driven Laboratory: Opportunities in the New Marketplace.
She earned her M.D. at Baylor College of Medicine, completed pathology residency at University of California San Francisco, and received an M.B.A. from Harvard Business School with highest honors (Baker Scholar).
President, Slone Partners
Tara Kochis is President of Slone Partners. She brings over a decade of solid healthcare experience to the company, which she joined in 2004, having been consistently ranked as one of the top-producing sales representatives with industry leaders such as VERSYSS, American Medical Laboratories, and Quest Diagnostics. Her highly successful, award-winning sales career covered a variety of healthcare segments, including information technology, medical records, and most importantly, the diagnostic and laboratory testing industries. Prior to healthcare, Ms. Kochis honed her recruitment skills in the banking and finance sector, filling a wide variety of financial positions.
Her executive recruitment skills coupled with her extensive healthcare background help her quickly and accurately assess candidates for the benefit of Slone Partners’ clients. Ms. Kochis graduated cum laude, receiving a Bachelor of Science, with a concentration in Human Resources Management, from Boston College. She is an active member of AACC, ACHE, and CLMA.
President and CEO, Calloway Laboratories, Inc.
Gail Marcus is a senior health care executive with more than 25 years' experience managing and growing domestic and international businesses. Since October 2012 she has served as President and CEO of Calloway Laboratories, Inc., one of the nation's fastest growing toxicology labs.
Ms. Marcus previously served as chief administrative officer for Hartford Healthcare and before that, she was a Partner and Healthcare Segment Leader for Tatum LLC eastern region and an advisor and consultant to health care services organizations, including hospital systems, managed care organizations and diagnostic companies.
From 2006-2008, she was President and CEO of Caris Diagnostics, a privately held laboratory company. Under her leadership, Caris became one of the nation’s leading aggregators of anatomic and molecular diagnostic services.
Prior to her tenure with Caris Diagnostics, Ms. Marcus served as Chief Operating Officer for United HealthCare European Operations, building a complete health care consulting and services business. Before joining United Health Care, she served as Senior Vice President and Chief Product and Revenue Officer at Advance PCS Pharmacy Benefits Management, where she also led the post-merger integration with Caremark.
Ms. Marcus spent more than 20 years at CIGNA HealthCare in various financial, product, strategy and marketing roles, including Assistant Treasurer; Vice President and Controller; Senior Vice President, Product Development; and Senior Vice President, Chief Operating Officer, International Operations. While based in the UK, Ms. Marcus was assigned as a turn-around specialist for the troubled overseas life and health businesses.
Marcus holds an MBA in finance from The Wharton School and an MS in information sciences from the University of Pennsylvania. She received a BA in mathematics and Spanish from Wesleyan University. She is an adjunct professor at the University of Connecticut business school, teaching health care courses in the MBA program. She sits on the boards of Susan G. Komen for the Cure, Connecticut affiliate, where she is chair of the Grants Committee; Bako Pathology; XpertDoc; and the Commission for Case Management.
President, American Clinical Laboratory Association
Since becoming President of ACLA in 2003, Alan Mertz has overseen a more than tripling of ACLA’s membership, greater visibility of ACLA in Congress and the Administration, expansion of ACLA membership services, meetings and programs, and a series of key advocacy successes.
ACLA took the lead in opposing a provision in the 2003 Medicare Modernization Act that would have added coinsurance for laboratory services in Medicare. From 2004-2008, ACLA led an advocacy campaign to stop the Medicare Laboratory Competitive Bidding Demonstration Project which resulted in, first, a federal court injunction against the project, followed by the statutory repeal of the project in June 2008. During the consideration of health care reform legislation in 2009-2010, ACLA took the lead in opposing proposals for a new federal tax on laboratory services as well as another attempt to impose laboratory coinsurance. In the same legislation, ACLA supported expanding coverage for the uninsured, a fair application of the “Productivity Adjustment,” provisions promoting prevention and wellness, extension of the so-called “TC Grandfather Clause,” and the “Date of Service” Demonstration.
In 2007, ACLA launched the “Results for Life” educational campaign aimed at promoting the value of laboratory services. In 2009, ACLA started its growing Associate Member program for non-laboratory health care companies and organizations as a means of broadening education and communication with the laboratory industry’s health partners.
Prior to taking the reins at ACLA, Mertz was Executive Vice President and Acting President of the Healthcare Leadership Council (HLC), and from 1980 to 1998 served in three senior staff positions in the House and Senate. He was selected as a John C. Stennis Congressional Fellow in 1996, taught as an adjunct professor at George Washington University from 1997-1999, and is a frequent lecturer at American University in Washington, DC. He holds a Masters Degree in American Politics from American University and a BA in Government from Monmouth College.
Managing Director, G2 Intelligence
Stephanie Murg is the Managing Director of G2 Intelligence, responsible for the live events business line as well as thought leadership roles in G2’s market research and advisory services.
Prior to joining G2, she was a research associate at JPMorganChase, Harvard Business School, and the National Bureau of Economic Research. She also has several years of laboratory experience in molecular and behavioral neuroscience research, with a focus on neurodegenerative disease.
Murg co-authored peer-reviewed publications in the Journal of Neuroscience, Human Gene Therapy, and Neurobiology of Learning and Memory, and co-wrote a chapter in the most recent edition of the textbook Neuropsychology of Memory. She received a bachelor’s degree in neurobiology from Harvard.
Jane Pine Wood
Member, McDonald Hopkins
Jane Pine Wood, a member in the national Healthcare Practice Group at McDonald Hopkins law firm, has been elected by her peers to serve on the firm’s Board of Directors. Wood joined McDonald Hopkins in 1988 and is a nationally respected healthcare attorney who has given hundreds of speeches throughout the country to various healthcare groups. She counsels more than 450 pathology groups and numerous clinical labs.
Wood represents a variety of healthcare providers—physicians, clinical, anatomic and molecular laboratories, imaging centers, home health agencies, mental health providers, clinics, hospitals, and others. She advises her clients on a wide range of corporate, regulatory, reimbursement, contractual, and other issues. A prolific writer, Wood has written numerous articles for healthcare periodicals. She also is a frequent presenter at national and regional conferences and seminars
Wood received a J.D. degree in 1987 from Vanderbilt University School of Law and a B.A. degree from Texas A & M University, summa cum laude, in 1983. She is admitted to practice law in two states—Massachusetts and Ohio—and serves on the Cape Cod Hospital Ethics Committee.
President, Health Care Development Services, Inc.
Barry Portugal is President of Health Care Development Services, Inc., a strategic business planning management consulting firm. Mr. Portugal has undergraduate and graduate degrees in business administration from the University of Illinois and the University of Pennsylvania, respectively. He also attended Northwestern Law School.
Prior to forming Health Care Development Services, Inc., in 1981, Mr. Portugal held several senior management positions with firms in the health care industry. During the 13 years Mr. Portugal spent on the corporate side of the industry, he served as sales manager, marketing manager, and corporate officer in charge of marketing for Technicon Instruments Corporation; Telemed Corporation, a division of Becton-Dickinson; and Damon Corporation.
Mr. Portugal consults with hospitals, large multi-specialty group practices, clinical laboratories, and pathology groups. His special area of interest is strategic planning and business development of health care providers. In this role, Mr. Portugal has designed business plans which have successfully achieved goals desired by client organizations.
Mr. Portugal is a member of the American Hospital Association Society for Hospital Planning, Clinical Laboratory Management Association, the American Association for Clinical Chemistry, the American Pathology Foundation, and the Medical Group Management Association. Additionally, Mr. Portugal has had written articles published in Clinical Laboratory Management Review, Pathologist, and the Medical Group Management Association Journal. He has been a featured speaker at meetings of the American Hospital Association, Health Care Financial Management Association, American College of Healthcare Executives, Clinical Laboratory Management Association, and the American Pathology Foundation, focusing on hospital laboratory strategic planning and business development.
George Poste, D.V.M., D.Sc., Ph.D.
Chief Scientist, Complex Adaptive Systems Initiative; Regents' Professor; and Del E. Webb Chair in Health Innovation, Arizona State University
George Poste is Chief Scientist, Complex Adaptive Systems Initiative (CASI), Regents’ Professor and Del E. Webb Chair in Health Innovation at Arizona State University. He assumed this post in February 2009. This program links expertise across the university in research on synthetic biology, ubiquitous sensing and healthcare informatics for personalized medicine.
He founded the Biodesign Institute at ASU and served as Director for 2003 to 2009. In creating this Institute, Dr. Poste designed and built 400,000 sq. ft. of new facilities, achieved cumulative research funding of $300 million and recruited over 60 faculty, including three members of the National Academies of Science and Engineering.
He serves on the Board of Directors of Monsanto (since 2003), Exelixis (since 2004), Caris Life Sciences (since 2005), and the Scientific Advisory Board of Synthetic Genomics (since 2009). From 1992 to 1999 he was Chief Science and Technology Officer and President, R&D of SmithKline Beecham (SB). During his tenure at SB he was associated with the successful registration of 31 drug, vaccine and diagnostic products. In 2004 he was named as ‘R&D Scientist of the Year’ by R&D Magazine, in 2006 he received the Einstein award from the Global Business Leadership Council and in 2009 received the Scrip Lifetime Achievement award voted by the leadership of the global pharmaceutical industry.
He has published over 350 research papers and edited 14 books on pharmaceutical technologies and oncology. He has received honorary degrees in science, law and medicine for his research contributions and was honored in 1999 by HM Queen Elizabeth II as a Commander of the British Empire for his contributions to international healthcare and security.
He is a Fellow of the Royal Society, the Royal College of Pathologists and the UK Academy of Medicine, a Distinguished Fellow at the Hoover Institution, Stanford University and a member of the Council for Foreign Relations. He served as a member of the Defense Science Board from 2003 to 2009 and Health Board of the US Department of Defense (DoD) and is currently a member of the US Institute of Medicine Board on Global Health. He has served as a member of Advisory Committees for multiple U.S. Government Agencies in areas of defense, national security and healthcare.
CEO, Siemens Healthcare Diagnostics
Mr. Michael Reitermann serves as the Chief Executive Officer of Diagnostics Division of Siemens AG and Siemens Medical Solutions USA, Inc. Mr. Reitermann has been the Chief Executive Officer at Siemens Healthcare Diagnostics, Inc. since April 30, 2010. He served as the Chief Executive Officer of Siemens Healthcare Diagnostics Limited since April 30, 2010. Mr. Reitermann served as the Chief Executive Officer of U S at Siemens Healthcare since July 2009 and was responsible for sales, marketing, service and logistics across the Siemens Healthcare portfolio, including medical imaging equipment, healthcare information technology, and medical therapy. Mr. Reitermann served as President of Medical Solutions Nuclear Medicine Group of Siemens Medical Solutions USA, Inc. since July 2002. He served as the Chief Executive Officer of Siemens Molecular Imaging Business Unit and the former Nuclear Medicine Division at Siemens Medical Solutions. He was responsible for the establishment and implementation of the Molecular Imaging Division's business objectives around the world, as well as the Division's overall financial performance. He served as Vice President for Sales and Marketing of Angiography and X-ray Division (AX) at Siemens. In this position, he was responsible for the worldwide marketing and promotion of Siemens AX products, including the successful AXIOM product line. From 1996 to 1998, he was a Partner in Siemens Management Consulting, conducting consulting projects in the areas of benchmarking, strategy and productivity. Prior to 1996, he served as a Consultant, then a Senior Project Manager at the corporate strategies division of Siemens Corporate Planning and Development. He serves as a Member of Board of Governors at National Electrical Manufacturers Association. Mr. Reitermann was educated at Hans-Grueninger-Gymnasium in Markgroeningen, Germany. He received a graduate degree in Industrial Engineering from the University of Karlsruhe, Germany, and a Master's of Business Administration from the University of British Columbia, Canada.
Managing Editor, G2 Intelligence
As Managing Editor, Kimberly Scott oversees publication of G2 Intelligence’s newsletters: Laboratory Industry Report; G2 Compliance Report; National Intelligence Report; and Diagnostic Testing & Technology Report.
She has 25 years of experience covering health care issues, both on a national and local level. Since 2001, Kimberly has covered the clinical laboratory and diagnostic testing industries, with an emphasis on business strategy, operations, and compliance. Prior to that, she covered long-term care, mental health, and disability issues for business-to-business publications and wrote about federal health care for U.S. Medicine. Kimberly got her start in writing and reporting at the Daytona Beach News-Journal, where she worked first as a general assignment reporter, and later covered the medical beat.
She has a bachelor’s degree in journalism from Florida Southern College and a master’s degree in English from the University of Maryland.
CEO, TriCore Reference Laboratories
As CEO, Khosrow Shotorbani has overall responsibility for TriCore Reference Laboratories’ operations, growth and financial health. He also leads TriCore’s initiative to improve health outcomes and lower costs by using laboratory medicine to guide the utilization of other types of medical care.
Before joining TriCore in 2014, Mr. Shotorbani served as senior vice president and director of business innovations at Associated Regional and University Pathologists (ARUP). He joined ARUP in 1984 as a medical technologist and advanced to positions of progressive responsibility over his 30-year tenure there.
Mr. Shotorbani holds a master’s degree in business administration from the University of Phoenix and a bachelor’s degree in clinical laboratory science from Weber State University in Ogden, Utah. He is a member of the American College of Healthcare Executives and the Clinical Laboratory Management Association, among other industry-related organizations.
Partner, Artiman Ventures
Ajit focuses on early-stage Technology and Life Science investments. He is on the board for Aditazz, CardioDx, and Oncostem.
Ajit is also a Consulting Professor in the School of Medicine at Stanford University and serves on the Board of Directors of Max Healthcare based in New Delhi, India.
Prior to joining Artiman, Ajit was the President and CEO of BioImagene, a Digital Pathology company specializing in Cancer Diagnostics, based in Sunnyvale, CA. BioImagene was acquired by Roche in September 2010. Before BioImagene, Ajit spent nearly twenty years at Siemens in various roles, most recently as the Chief Executive Officer of the Digital Radiology and Medical Informatics business of Siemens Healthcare, based in Germany. From 2001 to 2006, Ajit was the President and CEO of the Oncology Care Systems Group of Siemens, with global headquarters in Concord, California. Between 1996 and 2001, Ajit held the positions of Group Vice President of Siemens e-Health, and Vice President of Siemens Health Services based in Princeton, NJ, where he led the company's Healthcare IT business and Consulting Practice. Before transitioning to these business responsibilities, Ajit spent several years in R&D and academia. From 1989 to 1995, he was at Siemens Corporate Research in Princeton, responsible for research in the areas of artificial intelligence, robotics, computer vision, and image analysis. During this time, he concurrently served on the faculty at Princeton University.
Ajit has a Ph.D. in Computer Science from Columbia University, a master's degree in Computer Engineering from Syracuse University and a bachelor's degree in Electrical Engineering from Banaras Hindu University, India. He has published two books and numerous refereed articles, and holds five patents.
Douglas M. VanOort,
Chairman of the Board of Directors and Chief Executive Officer, NeoGenomics Laboratories
Mr. VanOort has served as the Chairman of the Board of Directors and Chief Executive Officer of NeoGenomics since October 28, 2009. Prior to that he served as Chairman of the Board of Directors, Executive Chairman and Interim Chief Executive Officer from March 2009 to October 2009. He has been an Operating Partner with Summer Street Capital Partners since 2004 and a Founding Partner of Conundrum Capital Partners since 2000. From 1995 to 1999, he served as the Senior Vice President Operations for Quest Diagnostics, Incorporated. During this period Quest Diagnostics grew to approximately $1.5 billion in annual revenue through both organic growth and mergers and acquisitions. From 1982 to 1995, Mr. VanOort served in various positions at Corning Incorporated and ultimately held the position of Executive Vice President and CFO of Corning Life Sciences, Inc. In 1995, Corning spun off Corning Life Sciences, Inc. into two companies, Quest Diagnostics and Covance, Inc. Mr. VanOort serves as a member of the Board of Directors of several privately held companies. In addition, since 2000, Mr. VanOort is the Co-Owner of Vision Ace Hardware, LLC, a retail hardware chain. Mr. VanOort is a graduate of Bentley University.
Principal/CEO, DV & Associates, Inc.
Having been Director of Sales and Marketing and Senior Consultant for a national coding and reimbursement firm for nearly five years, Diana Voorhees developed DV & Associates, a coding and reimbursement firm that provides consulting for physicians and facilities in all specialties. Ms. Voorhees has created a network of consultants with various health care backgrounds in order to provide quality, credible, and resourceful results for all consulting services. DV & Associates has been incorporated in excess of 14 years.
Ms. Voorhees initiated her career in laboratory medicine within the Division of Hematology, Department of Medicine, at the University of Utah. She has also worked with the Division of Hematology at The Ohio State University, the Clinical Chemistry Department at Holy Cross Hospital in Salt Lake City, and the Special Hematology and Hemostasis Laboratory at the University of Utah. She spent 14 years as an Associate Clinical Professor and administrative faculty of Medical Laboratory Sciences in the College of Pharmacy at the University of Utah. During her last year and a half in academia, she was recruited as Program Director to design, implement, and direct the program in cytotechnology in the Department of Pathology.
Upon leaving the university setting, Ms. Voorhees joined Coulter Corporation and provided technical support, customer training, and education, primarily in the western United States. She was recruited by a national coding and reimbursement consulting firm, Med-Index/Medicode, where she spent nearly five years developing and marketing the consulting services for hospitals and other facilities, performing consulting engagements, providing seminars for national associations, enhancing product development, and serving on various corporate committees.
Ms. Voorhees has authored/edited several articles for professional publications including Compliance Report, a monthly column in Advance Newsmagazine, MLO, Lab Medicine, ASCLS Newsletter, G2 Compliance Report, National Intelligence Report, and the Laboratory Compliance Insider newsletters. She has provided numerous seminars, teleconferences and audio conferences for various companies and organizations. Additionally, she completed a chapter on coding and reimbursement for a well-known textbook on administration.
Ms. Voorhees consults in pathology, radiology, oncology, and other diagnostic and therapeutic specialties. Her firm consults in all physician specialties and in all outpatient settings.
Wayne Wecksler, Ph.D.
General Manager, Pacific Diagnostic Laboratories
Wayne Wecksler, Ph.D. has been the General Manager at Pacific Diagnostic Laboratories since 2011. He received a doctorate in Biochemistry from the University of California, Riverside in 1978 and an MBA from UCLA in 1989.
Dr. Wecksler did his dissertation research on the mechanism of action of 1,25- dihydroxy-vitamin D. After a postdoctoral research fellowship at the French National Institutes of Health in Paris, he began his clinical laboratory career at Bio-Science Laboratories in Van Nuys, California. Bio-Science Laboratories eventually was acquired by SmithKline Beecham Clinical Laboratories and then Quest Diagnostics Laboratories.
During his twenty-four year career, Dr. Wecksler has held a number of positions in both R&D and Laboratory Operations, including two years as Operations Manager for Northern California for BioScience Laboratories and nine years as Technical Director and General Manager for SmithKline Beecham’s National Esoteric Testing Center in Van Nuys. During his last three years with SmithKline Beecham, he also had divisional responsibility for their Research and Technology Acquisition functions. Dr. Wecksler has published a number of original research papers in the areas of biochemistry, infectious diseases, and laboratory medicine.
Executive Editor, G2 Intelligence and Program Chair
One of the nation’s leading experts on the clinical diagnostic laboratory and pathology sectors, Dennis Weissman is President of Dennis Weissman & Associates, LLC and founder and Executive Editor of G2 Intelligence, an independent news and information company serving the health care industry.
Founded in 2004, Dennis Weissman & Associates, LLC provides public policy and strategic business intelligence and advice for the health care industry. Dennis is a well-known speaker before health care professional and industry trade groups nationwide. Prior to founding Washington G-2 Reports in 1979, he was Director of the Washington Office of the American Society for Medical Technology, and before that, worked as Special Assistant in the Office of the nation’s top health official in the U.S. Department of Health, Education, and Welfare.
He holds a bachelor’s degree in political science from the State University of New York at Buffalo and a master’s degree in higher education administration from Indiana University.
Conference Wi-Fi compliments of: